- 询价
- 2026年06月27日
15 年金牌会员
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 品系：
BALB/cfC3H
- 相关疾病：
肿瘤
- ATCC Number：
CRL-2539™
- 器官来源：
乳腺
- 物种来源：
小鼠
- 是否是肿瘤细胞：
0
- 细胞形态：
上皮样
- 运输方式：
冻存运输
- 生长状态：
贴壁生长
- 库存：
大量
| Designations: | 4T1 | ||
| Depositors: | BA Pulaski | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | adherent | ||
| Organism: | Mus musculus deposited as mouse | ||
| Morphology: | epithelial |
||
| Source: | Organ: mammary gland Strain: BALB/cfC3H Disease: tumor |
||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Applications: | 4T1-induced tumors can be used as a post-operative model as well as a non-surgical model because the 4T1-induced tumor metastasizes spontaneously in both models with similar kinetics. Because 4T1 is resistant to 6-thioquanine, micro-metastatic cells (as few as 1) can be detected in many distant site organs with better accuracy that most tumor models. When injected into BALB/c mice, 4T1 spontaneously produces highly metastatic tumors that can metastasize to the lung, liver, lymph nodes and brain while the primary tumor is growing in situ. |
||
| Tumorigenic: | Yes | ||
| Comments: | 4T1 is a 6-thioguanine resistant cell line selected from the 410.4 tumor without mutagen treatment. When injected into BALB/c mice, 4T1 spontaneously produces highly metastatic tumors that can metastasize to the lung, liver, lymph nodes and brain while the primary tumor is growing in situ. The primary tumor does not have to be removed to induce metastatic growth. The tumor growth and metastatic spread of 4T1 cells in BALB/c mice very closely mimic human breast cancer. This tumor is an animal model for stage IV human breast cancer. 4T1-induced tumors can be used as a post-operative model as well as a non-surgical model because the 4T1-induced tumor metastasizes spontaneously in both models with similar kinetics. Because 4T1 is resistant to 6-thioquanine, micro-metastatic cells (as few as 1) can be detected in many distant site organs with better accuracy that most tumor models. There is no need to count nodules or weight target organs. |
||
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0°C Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
||
| Subculturing: | Protocol: NOTE: the cells should not be allowed to become confluent, subculture at 80% of confluence. Remove medium, and rinse with 0.25% trypsin-0.53mM EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37.0°C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. Subcultivation Ratio: A subcultivation ratio of 1:6 to 1:8 is recommended Medium Renewal: Every 2 to 3 days |
||
| Preservation: | Freeze medium: Complete growth medium 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor temperature |
||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020 |
||
| References: | 49687: Pulaski BA, et al. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol. Immunother. 49: 34-45, 2000. PubMed: 10782864 49688: Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493, 1998. PubMed: 9537252 49689: Pulaski BA, et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res. 60: 2710-2715, 2000. PubMed: 10825145 49690: Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405, 1992. PubMed: 1540948 |
||
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验相关实验
「少吃」真的可以帮助杀死癌细胞！模拟禁食可重塑机体免疫，提高癌症免疫治疗的效果
免疫反应，并可减少其副作用。 禁食模拟饮食可以作用于肿瘤微环境，增加了低免疫原性的三阴性乳腺肿瘤（TNBC）中免疫治疗（抗 PD-L1 和抗 OX40）的效果。此外，FMD 还可以通过阻止免疫反应的过度激活，减少免疫相关不良事件（irAEs）的发生。 图片来源：Cell Reports 主要研究内容 禁食模拟饮食联合抗 OX40/抗 PD-L1 可阻止乳腺癌的进展 首先，研究人员将 4T1 乳腺癌细胞原位植入小鼠乳腺脂肪垫，然后用抗 OX40/抗 PD-L1 单独或联合治疗，并设置禁食模拟饮食
Nature：癌症疫苗新突破！调动 T 细胞与 NK 细胞的双重攻击，全面杀灭癌细胞
免疫 4 个月后，他们用肿瘤细胞重新攻击无肿瘤小鼠，发现其可完全受到保护。 另外，利用两个自发转移模型，B16-BL6 黑色素瘤模型和 4T1 三阴性乳腺癌模型。他们发现在切除原发肿瘤后，小鼠在接种了 MICB-vax 或 Ctrl-vax 后，MICB-vax 可显著降低两种模型术后 1 个月以上的肺转移数量。肺组织切片的组织学分析进一步表明，与 Ctrl-vax 相比，MICB-vax 可显著减少转移数量和转移大小。 他们还在恒河猴中检测了疫苗的安全性和免疫原性，发现抗 MICA 和抗 MICB
「神药」再显威！杨黄浩等让二甲双胍扮演 PD-L1 「单抗」角色，提高治疗效果
-L1 定位（荧光共定位）等不同的角度进行分析，验证了纳米片 MS NPs 可以介导内源性的 PD-L1 表达降低。 图片来源：Theranostics 是骡是马，得拿出来遛一遛。研究团队又将纳米片 MS NPs 用于治疗 4T1 荷瘤小鼠，同时设置了不同的对照组：生理盐水组、PD-L1 抗体治疗组、二甲双胍 Met 组、单纯化疗 SN38 组、Met/SN38 序贯治疗组。结果发现，与对照组小鼠相比， MS NPs 组的小鼠肿瘤生长被显著抑制，小鼠的生存时间显著延长。 图片来源：Theranostics
技术资料暂无技术资料 索取技术资料
4T1
询价
